Article Dans Une Revue Nuclear Medicine Communications Année : 2017

67Cu-Radiolabeling of a multimeric RGD peptide for αVβ3 integrin-targeted radionuclide therapy

Résumé

Objective Copper-67 (67Cu) is one of the most promising radionuclides for internal radiation therapy. Globally, several projects have recently been initiated for developing innovative approaches for the large-scale production of 67Cu. Encouraged by these, we performed 67Cu-radiolabeling of a tetrameric cyclic Arg–Gly–Asp (cRGD) peptide conjugate, cyclam-RAFT-c(-RGDfK-)4, which selectively targets αVβ3 integrin (αVβ3), the transmembrane receptor involved in tumor invasion, angiogenesis, and metastasis. We also evaluated the therapeutic potential and safety of this radiocompound. Materials and methods 67Cu, produced through the 64Ni(α, p)67Cu reaction, was used for the radiolabeling of cyclam-RAFT-c(-RGDfK-)4 at 70°C for 10 min. The radiolabeling efficiency and product stability were assessed using reversed-phase high-performance liquid chromatography and/or thin-layer chromatography. Mice with subcutaneous αVβ3-positive U87MG-glioblastoma xenografts received a single intravenous injection of one of the following: 67Cu-cyclam-RAFT-c(-RGDfK-)4 (11.1 MBq), peptide control, or vehicle solution. The tumor volumes were measured, side effects were assessed in terms of body weight, routine hematology, and hepatic and renal functions, and the mouse radiation dosimetry was estimated. Results 67Cu-cyclam-RAFT-c(-RGDfK-)4 was produced with a radiochemical purity of 97.9±2.4% and a specific activity of 2.7±0.6 MBq/nmol and showed high in-vitro and in-vivo plasma stability. The administration of a single dose of 67Cu-cyclam-RAFT-c(-RGDfK-)4 resulted in significant tumor growth delay in comparison with that observed upon vehicle or peptide control administration, with an estimated tumor-absorbed dose of 0.712 Gy. No significant toxicity was observed in 67Cu-cyclam-RAFT-c(-RGDfK-)4-treated mice. Conclusion 67Cu-cyclam-RAFT-c(-RGDfK-)4 would be a promising therapeutic agent for αVβ3 integrin-targeted internal radiotherapy.

Domaines

Fichier non déposé

Dates et versions

hal-01636938 , version 1 (17-11-2017)

Identifiants

Citer

Zhao-Hui Jin, Takako Furukawa, Tomoyuki Ohya, Melissa Degardin, Aya Sugyo, et al.. 67Cu-Radiolabeling of a multimeric RGD peptide for αVβ3 integrin-targeted radionuclide therapy. Nuclear Medicine Communications, 2017, 38 (4), pp.347 - 355. ⟨10.1097/MNM.0000000000000646⟩. ⟨hal-01636938⟩
184 Consultations
0 Téléchargements

Altmetric

Partager

  • More